Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease

British Journal of Clinical Pharmacology

Volumn 70, Issue 3, 2010, Pages 400-408

  D'Esposito, Fabrizio ^a   Nebot, Noelia ^a   Edwards, Robert J ^b   Murray, Michael ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Carboxylesterase; CYP3A4; Irinotecan; Liver disease

Indexed keywords

7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALBUMIN; AMPICILLIN; ATENOLOL; BILIRUBIN; CARBOXYLESTERASE; CEFOTAXIME; CIMETIDINE; CIPROFLOXACIN; CYTOCHROME P450 3A4; DRUG METABOLITE; FUROSEMIDE; HYDROCORTISONE; INSULIN; IRINOTECAN; MORPHINE; NORFLOXACIN; OMEPRAZOLE; OXAZEPAM; PETHIDINE; PREDNISONE; PROPRANOLOL; RANITIDINE; RIFAMPICIN; SPIRONOLACTONE; SUCRALFATE; THYROXINE; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DOWN REGULATION; DRUG HYDROLYSIS; DRUG TRANSFORMATION; HUMAN; IN VITRO STUDY; LIVER DYSFUNCTION; LIVER MICROSOME; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CAMPTOTHECIN; CARBOXYLESTERASE; CHRONIC DISEASE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMANS; LIVER DISEASES; MICROSOMES, LIVER;

EID: 77955744377     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03715.x     Document Type: Article

References (34)

1. Haaz MC, Rivory L, Riché C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 1998 58 : 468 472.
2. Humerickhouse R, Lohrbach K, Li L, Bosron W, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000 60 : 1189 1192.
3. Mathijssen RHJ, van Alphen RJ, Verweij J, Loos WL, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001 7 : 2182 2196.
4. Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1996 14 : 2688 2695.
5. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998 101 : 847 854.
6. Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP, Robert J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 1997 3 : 1261 1266.
7. Kehrer DF, Yamamoto W, Verweij J, de Jonge MJ, de Bruijn P, Sparreboom A. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res 2000 6 : 3393 3394.
8. Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M, Misset JL, Cvitkovic E. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997 8 : 1049 1051.
9. Van Groeningen CJ, Van der Vijgh WJF, Baars JJ, Stieltjes H, Huibregtse K, Pinedo HM. Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines. Clin Cancer Res 2000 6 : 1342 1346.
10. Ong SYK, Clark SJ, Bishop J, Dodds HM, Rivory LP. Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anticancer Drugs 2001 12 : 619 625.
11. Raymond E, Boige V, Faivre S, Sanderink GJ, Rixe O, Vernillet L, Jacques C, Gatineau M, Ducreux M, Armand JP. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002 20 : 4303 4312.
12. Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003 14 : 1783 1790.
13. Schaaf LJ, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, Miller LL, Compton LD, Cisar LA, Elfring GL, Gruia G, McGovren JP, Pirotta N, Yin D, Sharma A, Duncan BA, Rothenberg ML. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. Clin Cancer Res 2006 12 : 3782 3791.
14. Edwards RJ, Adams DA, Watts PS, Davies DS, Boobis AR. Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. Biochem Pharmacol 1998 56 : 377 387.
15. Child CG, Turcotte JG. Surgery and portal hypertension. In : The Liver and Portal Hypertension, ed. Child CG. Philadelphia, PA : WB Saunders, 1964 50 64.
16. Pugh RN, Murray-Lyon IM, Dawson JL, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973 60 : 646 649.
17. Murray M, Cantrill E, Farrell GC. Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide. J Pharmacol Exp Ther 1993 265 : 477 481.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951 193 : 265 275.
19. d'Esposito F, Tattam BN, Ramzan I, Murray M. A liquid chromatography/electrospray ionization mass spectrometry (LC/MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples. J Chromatogr B 2008 875 : 522 530.
20. Kanazawa H, Okada A, Igarashi E, Higaki M, Miyabe T, Sano T, Nishimura R. Determination of midazolam and its metabolite as a probe for cytochrome P450 3A4 phenotype by liquid chromatography-mass spectrometry. J Chromatogr A 2004 1031 : 213 218.
21. Vielnascher E, Spatzenegger M, Mayrhofer A, Klinger P, Jäger W. Metabolism of dextromethorphan in human liver microsomes: a rapid HPLC assay to monitor cytochrome P450 2D6 activity. Pharmazie 1996 51 : 586 588.
22. Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 1997 25 : 1157 1164.
23. Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G, Verweij J. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998 4 : 2747 2754.
24. Wilkinson GR, Schenker S. Drug disposition and liver disease. Drug Metab Rev 1975 4 : 139 175.
25. Howden CW, Birnie GG, Brodie MJ. Drug metabolism in liver disease. Pharmacol Ther 1989 40 : 439 474.
26. Congiu M, Mashford ML, Slavin JL, Desmond PV. UDP-glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 2002 30 : 129 134.
27. Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Herait P, Armand JP, Bugat R, Clavel M, Marty ME. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995 6 : 141 151.
28. Chalasani N, Gorski JC, Patel NH, Hall SD, Galinsky RE. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology 2001 34 : 1103 1108.
29. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 1992 51 : 229 238.
30. George J, Murray M, Byth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995 21 : 120 128.
31. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991 256 : 1189 1194.
32. Mathijssen RHJ, de Jong FA, van Schaik RHN, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 2004 96 : 1585 1592.
33. Corona G, Vaccher E, Sandron S, Sartor I, Tirelli U, Innocenti F, Toffoli G. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther 2008 83 : 601 606.
34. Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002 20 : 3122 3129.